FBLG (FibroBiologics) EBITDA Margin %: 0.00% (As of Mar. 2026)


FBLG FibroBiologics Inc FBLG
13 GF Score
Price $0.87
! 3 Warning Signs
View Full Analysis

What is FibroBiologics EBITDA Margin %?

FibroBiologics FBLG +17.71% 13 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates FBLG with a GF Score™ of 13/100. The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, FibroBiologics ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. FibroBiologics's EBITDA for the three months ended in Mar. 2026 was $-4.76 Mil. FibroBiologics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, FibroBiologics's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

FibroBiologics  (NAS:FBLG) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

FibroBiologics EBITDA Margin % Related Terms

FibroBiologics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for FibroBiologics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FibroBiologics EBITDA Margin % Chart

FibroBiologics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
0.00 0.00 0.00 0.00 0.00

FibroBiologics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FBLG vs BGMS, AIM, APVO: EBITDA Margin % Comparison

For the Biotechnology subindustry, FibroBiologics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FibroBiologics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroBiologics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where FibroBiologics's EBITDA Margin % falls into.


FBLG
13GF Score
FibroBiologics Inc FBLG
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

FibroBiologics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

FibroBiologics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-17.61/0
= %

FibroBiologics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-4.759/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
FibroBiologics (FBLG) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on FibroBiologics and its competitors. According to the industry distribution chart, FibroBiologics ranks #999999 out of 944 companies in the Biotechnology industry.
Is FibroBiologics' EBITDA Margin % too high?
FibroBiologics' current EBITDA Margin % is 0.00%. Based on the distribution chart, FibroBiologics ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, FibroBiologics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does FibroBiologics' EBITDA Margin % compare to BGMS and AIM?
According to the Biotechnology industry distribution chart, FibroBiologics ranks #999999 out of 944 companies for EBITDA Margin %. This places FibroBiologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on FibroBiologics and its competitors. FibroBiologics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FibroBiologics stock overvalued right now?
FibroBiologics (FBLG) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. FibroBiologics' overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For FibroBiologics (FBLG), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

FibroBiologics Business Description

Address 455 East Medical Center Boulevard, Suite 300, Houston, TX, USA, 77598
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
13GF Score

Get the complete analysis for FBLG

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.87
Price